Incyte Corp. (INCY) News

Incyte Corp. (INCY): $53.22

0.21 (-0.39%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

A

Add INCY to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#4 of 362

in industry

Filter INCY News Items

INCY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

INCY News Highlights

  • For INCY, its 30 day story count is now at 6.
  • Over the past 15 days, the trend for INCY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • GENE, TOP and ASH are the most mentioned tickers in articles about INCY.

Latest INCY News From Around the Web

Below are the latest news stories about INCYTE CORP that investors may wish to consider to help them evaluate INCY as an investment opportunity.

12 Most Promising Gene Editing Stocks According to Hedge Funds

In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can take a look at the 5 Most Promising […]

Yahoo | December 20, 2023

13 Most Promising Healthcare Stocks According to Analysts

In this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […]

Yahoo | December 19, 2023

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

John Blankenhorn on InvestorPlace | December 16, 2023

The 3 Most Undervalued Biotech Stocks to Buy in December

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Gabriel Osorio-Mazzilli on InvestorPlace | December 15, 2023

Incyte Stock Is the S&P 500’s Top Performer. Here’s Why It’s Surging.

Shares of biopharmaceutical company Incyte were on track Tuesday for their best trading session in more than six years. The stock rose 8.6% to $61.97 on Tuesday, putting Incyte shares on pace for their largest increase since Aug. 30, 2017, when they gained 11%, according to Dow Jones Market Data. It was the top performer in the on Tuesday.

Yahoo | December 12, 2023

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

WILMINGTON, Del. & WALTHAM, Mass., December 10, 2023--Incyte and Syndax Present Additional Data from AGAVE-201 Trial at ASH Plenary Showing Axatilimab Efficacy Including Durable Responses in Chronic GVHD

Yahoo | December 10, 2023

Incyte's Bullish Outlook: A Surprising Strength You Shouldn't Overlook

The company is a leader in the global myelofibrosis treatment market

Yahoo | December 5, 2023

Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 1, 2023

Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | November 30, 2023

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.

Yahoo | November 23, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!